Algert Global LLC Buys New Position in Ignyta, Inc. (NASDAQ:RXDX)
Algert Global LLC bought a new stake in Ignyta, Inc. (NASDAQ:RXDX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 64,433 shares of the biopharmaceutical company’s stock, valued at approximately $667,000. Algert Global LLC owned about 0.15% of Ignyta as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. boosted its stake in shares of Ignyta by 16.2% in the first quarter. Victory Capital Management Inc. now owns 2,804,834 shares of the biopharmaceutical company’s stock valued at $24,122,000 after buying an additional 390,741 shares during the last quarter. Broadfin Capital LLC boosted its stake in shares of Ignyta by 16.9% in the first quarter. Broadfin Capital LLC now owns 2,637,346 shares of the biopharmaceutical company’s stock valued at $22,681,000 after buying an additional 380,800 shares during the last quarter. Emerald Advisers Inc. PA acquired a new stake in shares of Ignyta during the second quarter valued at approximately $16,905,000. Vanguard Group Inc. boosted its stake in shares of Ignyta by 10.4% in the first quarter. Vanguard Group Inc. now owns 1,228,177 shares of the biopharmaceutical company’s stock valued at $10,562,000 after buying an additional 115,212 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Ignyta during the second quarter valued at approximately $12,018,000. Institutional investors own 52.96% of the company’s stock.
Shares of Ignyta, Inc. (RXDX) opened at 9.50 on Friday. The stock’s 50 day moving average price is $9.86 and its 200 day moving average price is $8.35. Ignyta, Inc. has a one year low of $4.15 and a one year high of $11.45. The company’s market cap is $475.59 million.
Ignyta (NASDAQ:RXDX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.07. Equities analysts predict that Ignyta, Inc. will post ($2.57) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Algert Global LLC Buys New Position in Ignyta, Inc. (NASDAQ:RXDX)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/11/algert-global-llc-buys-new-position-in-ignyta-inc-nasdaqrxdx.html.
RXDX has been the topic of several research analyst reports. ValuEngine upgraded Ignyta from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. BidaskClub cut Ignyta from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Jefferies Group LLC restated a “buy” rating and set a $27.00 target price on shares of Ignyta in a report on Thursday, June 22nd. Cantor Fitzgerald set a $15.00 target price on Ignyta and gave the stock a “buy” rating in a report on Monday, July 10th. Finally, Zacks Investment Research upgraded Ignyta from a “sell” rating to a “hold” rating in a report on Tuesday, May 30th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $17.33.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Want to see what other hedge funds are holding RXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ignyta, Inc. (NASDAQ:RXDX).
Receive News & Stock Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related stocks with our FREE daily email newsletter.